Wuxi Biologics (Cayman) (1FW2) Stock Statistics & Valuation Metrics
Total Valuation
Wuxi Biologics (Cayman) has a market cap or net worth of EUR 20.83B. The enterprise value is EUR 140.19B.
- Market Cap
- EUR 20.83B
- Enterprise Value
- EUR 140.19B
Share Statistics
Wuxi Biologics (Cayman) has 4,116,762,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,116,762,000
- Owned by Insiders
- ―
- Owned by Institutions
- 0.02%
Financial Efficiency
Wuxi Biologics (Cayman)’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 9.26%.
- Return on Equity (ROE)
- 0.10
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 9.26%
- Return on Capital Employed (ROCE)
- 0.12
- Revenue Per Employee
- 1.48M
- Profits Per Employee
- 333.79K
- Employee Count
- 14,705
- Asset Turnover
- 0.34
- Inventory Turnover
- 8.17
Valuation Ratios
The current PE Ratio of Wuxi Biologics (Cayman) is 31.13. Wuxi Biologics (Cayman)’s PEG ratio is 1.57.
- PE Ratio
- 31.13
- PS Ratio
- 6.56
- PB Ratio
- 3.21
- Price to FCF
- 35.04
- Price to Operating Cash Flow
- 17.04
- PEG Ratio
- 1.57
Income Statement
In the last 12 months, Wuxi Biologics (Cayman) had revenue of 21.79B and earned 4.91B in profits. Earnings per share was 1.16.
- Revenue
- 21.79B
- Gross Profit
- 10.02B
- Operating Income
- 6.64B
- Pretax Income
- 7.26B
- Net Income
- 4.91B
- EBITDA
- 8.37B
- Earnings Per Share (EPS)
- 1.16
Cash Flow
In the last 12 months, operating cash flow was 9.05B and capital expenditures -4.63B, giving a free cash flow of 4.42B billion.
- Operating Cash Flow
- 9.05B
- Free Cash Flow
- 4.42B
- Free Cash Flow per Share
- 1.08
Dividends & Yields
Wuxi Biologics (Cayman) pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.85%
- Earnings Yield
- 3.25%
Stock Price Statistics
- Beta
- 1.16
- 52-Week Price Change
- 27.93%
- 50-Day Moving Average
- 5.64
- 200-Day Moving Average
- 4.38
- Relative Strength Index (RSI)
- 35.14
- Average Volume (3m)
- 1,405
Important Dates
Wuxi Biologics (Cayman) upcoming earnings date is Mar 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 25, 2026
- Next Earnings Date
- Mar 23, 2027
- Ex-Dividend Date
- ―
Financial Position
Wuxi Biologics (Cayman) as a current ratio of 3.14, with Debt / Equity ratio of 6.57%
- Current Ratio
- 3.14
- Quick Ratio
- 2.97
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- -0.73
- Interest Coverage Ratio
- 47.65
Taxes
In the past 12 months, Wuxi Biologics (Cayman) has paid 1.52B in taxes.
- Income Tax
- 1.52B
- Effective Tax Rate
- 0.21
Enterprise Valuation
Wuxi Biologics (Cayman) EV to EBITDA ratio is 15.71, with an EV/FCF ratio of 33.65.
- EV to Sales
- 6.30
- EV to EBITDA
- 15.71
- EV to Free Cash Flow
- 33.65
- EV to Operating Cash Flow
- 16.44
Balance Sheet
Wuxi Biologics (Cayman) has EUR 13.04B in cash and marketable securities with EUR 2.73B in debt, giving a net cash position of EUR 10.31B billion.
- Cash & Marketable Securities
- EUR 13.04B
- Total Debt
- EUR 2.73B
- Net Cash
- EUR 10.31B
- Net Cash Per Share
- EUR 2.50
- Tangible Book Value Per Share
- EUR 12.56
Margins
Gross margin is 47.47%, with operating margin of 32.36%, and net profit margin of 21.20%.
- Gross Margin
- 47.47%
- Operating Margin
- 32.36%
- Pretax Margin
- 31.10%
- Net Profit Margin
- 21.20%
- EBITDA Margin
- 40.11%
- EBIT Margin
- 32.38%
Analyst Forecast
The average price target for Wuxi Biologics (Cayman) is EUR 6.70, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 6.70
- Price Target Upside
- 30.64% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 15
- Revenue Growth Forecast
- 13.33%
- EPS Growth Forecast
- 13.46%
Scores
- Smart Score
- 10
- AI Score
- ―